CDTX Cidara Therapeutics
- 12.3300
- -0.3000-2.38%
Cidara Therapeutics News
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
The first presentation highlights data from the Phase 2a study of CD388, showing the DFC was well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challenged with influenza.
Cidara Therapeutics Is Maintained at Buy by Needham
Cidara Therapeutics Is Maintained at Buy by Needham
Needham Maintains Buy on Cidara Therapeutics, Adjusts Price Target To $25
Needham analyst Joseph Stringer maintains Cidara Therapeutics with a Buy, adjusts target to $25 from $3.
Needham: Maintaining the Cidara Therapeutics (CDTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $3.00 to $25.00.
Needham: Maintaining the Cidara Therapeutics (CDTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $3.00 to $25.00.
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Caterpillar Inc. (NYSE:CAT) fell sharply during Thursday's session after the company reported better-than-expected first-quarter EPS but missed revenue estimates.Caterpillar reported a first
Cantor Fitzgerald Reiterates Overweight on Cidara Therapeutics
Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics with a Overweight.
Cidara Therapeutics Stock Jumps 13% As It Reacquires Rights To Influenza Drug
Cidara Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 — Cantor Fitzgerald Reiterates → Overweight 04/23/2024 — Cantor Fitzgerald Reiterates → Overw
Market-Moving News for April 25th
ULBI: 26% | Ultralife shares are trading higher after the company reported better-than-expected Q1 financial results.CDTX: 41% | Cidara Therapeutics shares are trading higher after the company announc
Top Premarket Gainers
Barfresh Food Group (BRFH) shares more than doubled Thursday premarket following a 5% increase on Wednesday. reAlpha Tech Corp. (AIRE) shares surged 33%, extending Wednesday's rally. Cidara Therapeuti
Cidara Therapeutics Shares Are Trading Higher After the Company Announced the Divestiture of Rezafungin to Mundipharma, Reacquired Global Development and Commercial Rights to CD388 and Announced $240 Million in Private Placement Financing.
Cidara Therapeutics Shares Are Trading Higher After the Company Announced the Divestiture of Rezafungin to Mundipharma, Reacquired Global Development and Commercial Rights to CD388 and Announced $240
Why Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Shares of Teradyne, Inc. (NASDAQ:TER) rose sharply in today's pre-market trading after the company posted upbeat first-quarter results and issued strong second-quarter forecast.Teradyne posted adjuste
Changes in US stocks 丨 Cidara Therapeutics rose more than 30% in the premarket to sell assets and adjust strategic priorities
Glonghui, April 25 | Biotech company Cidara Therapeutics continued to rise more than 30% to $16 in the premarket. The company said it will sell rezafungin, a treatment for candidosis, to partners and buy back its licenses for potential influenza prevention treatments. The sale is expected to save approximately $128 million during the patent's validity period, of which more than half will be spent on clinical development costs.
Cidara Therapeutics (CDTX) Stock Surge After-Hours On Strategic Divestment
Cidara Therapeutics (NASDAQ: CDTX) shares experienced a remarkable surge subsequent to the company's announcement regarding the transfer of rezafungin, an antifungal therapeutic, to its collaborator, Mundipharma. Cidara Therapeutics shares value soared by an impressive 40.68% to $17.29 during after-hours trading. The surge followed a substantial increase in CDTX stock on the US charts of 19.90% ...
Stocks to Watch: Meta Platforms, IBM, O'Reilly Automotive, Cidara Therapeutics
By Ben Glickman Meta Platforms said it would increase its spending for the year by as much as $10 billion to support its AI push, following a year of cost cuts in 2023. The Facebook parent's revenue
Cidara Therapeutics Shares Surge 30% After Reacquiring Flu Treatment
By Ben Glickman Shares of Cidara Therapeutics (CDTX) rose sharply after the company announced a reshuffling of its portfolio of drug candidates. The stock was up 33% to $16.43 in after-hours trading
Cidara Therapeutics Reacquires Global Development And Commercial Rights To CD388 From Johnson & Johnson For A One Time Payment Of $85M; Announces Private Placement Financing Of $240M
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinic
Cidara Therapeutics To Sell Candidiasis Treatment, Re-acquire Flu Asset
By Ben Glickman Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner and buy back the license to its potential influenza-prevention treatment. The San Diego-bas
Cidara Therapeutics Refocuses Strategy With Asset Sale
Cidara Therapeutics: Strategic Partnerships and Governance Changes
Analysis
Price Target
No Data
